CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
53.85
+0.33 (0.62%)
Aug 10, 2026, 12:31 PM EDT - Market open
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$34,076
Profits / Employee
-$1,147,936
Market Cap
5.21B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ACADIA Pharmaceuticals | 798 |
| Travere Therapeutics | 497 |
| Xenon Pharmaceuticals | 370 |
| Dyne Therapeutics | 263 |
| Edgewise Therapeutics | 154 |
| Definium Therapeutics | 106 |
| Dianthus Therapeutics | 92 |
CRSP News
- 3 days ago - Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs - TheFly
- 4 days ago - Crispr Therapeutics price target lowered to $82 from $83 at BofA - TheFly
- 4 days ago - Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs - TheFly
- 6 days ago - Citi ups Crispr Therapeutics target on Casgvey momentum - TheFly
- 6 days ago - Crispr Therapeutics price target raised to $88 from $82 at Citi - TheFly
- 6 days ago - Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18) - TheFly
- 6 days ago - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 6 days ago - CRISPR Therapeutics AG Earnings release: Q2 2026 - Filings